ARWR,PTGX Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.54
Percentage change 2.84	%

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: IJH VTI IWM VB VXF VBK XBI IWO MDY IBB

Index	RUT	P/E	-	EPS (ttm)	-5.00	Insider Own	6.90%	Shs Outstand	124.38M	Perf Week	5.79%
Market Cap	2.43B	Forward P/E	-	EPS next Y	-3.39	Insider Trans	-2.17%	Shs Float	115.84M	Perf Month	-12.56%
Income	-599.49M	PEG	-	EPS next Q	-0.41	Inst Own	76.44%	Short Float	8.64%	Perf Quarter	-7.30%
Sales	3.55M	P/S	685.62	EPS this Y	49.64%	Inst Trans	-0.48%	Short Ratio	6.58	Perf Half Y	-29.23%
Book/sh	1.49	P/B	13.12	EPS next Y	-34.60%	ROA	-62.93%	Short Interest	10.01M	Perf Year	-42.57%
Cash/sh	5.47	P/C	3.57	EPS next 5Y	-	ROE	-262.48%	52W Range	17.05 - 36.72	Perf YTD	4.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-58.15%	52W High	-46.73%	Beta	0.95
Dividend TTM	-	Quick Ratio	6.74	Sales past 5Y	-2.87%	Gross Margin	-423.66%	52W Low	14.72%	ATR (14)	1.13
Dividend Ex-Date	-	Current Ratio	6.74	EPS Y/Y TTM	-160.68%	Oper. Margin	-16927.06%	RSI (14)	47.89	Volatility	4.99% 5.48%
Employees	609	Debt/Eq	4.59	Sales Y/Y TTM	-98.52%	Profit Margin	-16882.37%	Recom	1.71	Target Price	43.42
Option/Short	Yes / Yes	LT Debt/Eq	4.56	EPS Q/Q	-34.15%	Payout	-	Rel Volume	0.61	Prev Close	19.02
Sales Surprise	-100.00%	EPS Surprise	-21.39%	Sales Q/Q	-100.00%	Earnings	Nov 26 AMC	Avg Volume	1.52M	Price	19.56
SMA20	1.37%	SMA50	-6.08%	SMA200	-14.68%	Trades		Volume	927,164	Change	2.84%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Jan-17-25 04:30PM	Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
Dec-24-24 08:20AM	Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial (Clinical Trials Arena)
Dec-23-24 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Dec-19-24 04:59PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 07:30AM	Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases (Business Wire)
07:40AM	Loading…
Dec-04-24 07:40AM	Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment (Clinical Trials Arena) -11.35%
Dec-03-24 07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
Dec-02-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences (Business Wire)
Nov-30-24 06:00AM	Arrowhead price target lowered to $24 from $27 at Bernstein (TipRanks)
Nov-29-24 01:00AM	Arrowhead Pharmaceuticals Faces Distribution Risks with Vanscoy Reliance (TipRanks)
Nov-28-24 08:15AM	Sarepta price target lowered to $202 from $205 at Needham (TipRanks)
Nov-27-24 12:40PM	Q4 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +24.23%
11:07AM	Arrowhead Stock Rockets 16% After Major Licensing Deal (GuruFocus.com)
07:21AM	Sarepta to pay Arrowhead $500M + in licensing deal for siRNA-based treatments (TipRanks)
07:20AM	Arrowhead to get $825M in Sarepta licensing pact, appoints Sarepta CEO to board (TipRanks)
04:33AM	Loading…
04:33AM	Arrowhead and Sarepta link for rare genetic disease treatments (Pharmaceutical Technology)
02:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2024 Earnings Call Highlights: Transformational ... (GuruFocus.com)
Nov-26-24 05:18PM	Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal (Investor's Business Daily) +12.03%
04:05PM	Arrowhead Pharma, Sarepta TX ink new gene therapy deal (Yahoo Finance Video)
04:00PM	Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results (Business Wire)
09:06AM	Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta (Investor's Business Daily)
07:00AM	Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs (Business Wire)
07:00AM	Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs (Business Wire)
Nov-22-24 07:41AM	Arrowhead Pharmaceuticals Inc. (ARWR): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-19-24 03:38AM	Arrowhead Pharmaceuticals submits plozasiran NDA to treat FCS (Pharmaceutical Business Review)
Nov-18-24 07:31AM	Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome (Business Wire)
07:30AM	Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran (Business Wire)
Nov-05-24 07:30AM	Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results (Business Wire)
Nov-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences (Business Wire)
Nov-01-24 07:30AM	Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, Well Get There Soon, to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome (Business Wire)
01:01PM	Loading…
Oct-16-24 01:01PM	State Street Corp's Strategic Acquisition in Arrowhead Pharmaceuticals (GuruFocus.com) +6.14%
Oct-14-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 05:53PM	Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Sep-24-24 06:53AM	Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand (Clinical Trials Arena)
Sep-23-24 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity (Business Wire)
Sep-11-24 06:12AM	FDA grants breakthrough therapy status to Arrowheads plozasiran (Pharmaceutical Technology)
Sep-10-24 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran (Business Wire)
Sep-03-24 10:36AM	Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug (Investopedia)
06:33AM	Arrowhead to file NDA after pivotal rare disease trial meets all endpoints (Clinical Trials Arena)
Sep-02-24 06:36AM	Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire)
Aug-21-24 07:30AM	Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome (Business Wire) +6.95%
Aug-16-24 06:00AM	Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance (BioPharma Dive)
Aug-15-24 10:52AM	Arrowhead announces push into obesity space with two gene therapies (Pharmaceutical Technology)
Aug-14-24 01:30PM	Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies (Business Wire)
Aug-08-24 04:37PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -9.44%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results (Business Wire)
04:00PM	Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street (Business Wire)
Jul-29-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-24-24 07:30AM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results (Business Wire)
Jun-28-24 06:50AM	Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025 (InvestorPlace)
Jun-25-24 01:55PM	Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial (Business Wire)
Jun-24-24 07:30AM	Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE (Business Wire) +6.82%
Jun-03-24 03:55PM	Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday? (Benzinga) +7.28%
07:30AM	Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome (Business Wire)
May-31-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences (Business Wire)
May-29-24 05:30AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-28-24 06:04AM	Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia (Business Wire)
May-20-24 11:04AM	Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients (MT Newswires)
06:00AM	Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma (Business Wire)
May-14-24 07:08AM	Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 (InvestorPlace)
May-10-24 01:03PM	Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging from Analyst Expectations (GuruFocus.com) -10.68%
12:26PM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript (Insider Monkey)
11:32AM	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating (MT Newswires)
May-09-24 11:54PM	ARWR Stock Earnings: Arrowhead Pharma Misses EPS for Q2 2024 (InvestorPlace)
04:34PM	Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2 (MT Newswires)
04:14PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results (Business Wire)
May-03-24 07:26AM	Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug (MT Newswires)
May-02-24 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
Apr-29-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences (Business Wire)
Apr-26-24 07:30AM	Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars (Business Wire)
Apr-24-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results (Business Wire) -6.10%
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease (Business Wire)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-07-24 09:00AM	Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo (Business Wire)
Apr-04-24 01:27AM	Insider Sell: Chief Discovery/Trans Medicine James Hamilton Sells 6,000 Shares of Arrowhead ... (GuruFocus.com)
Apr-01-24 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -7.26%
Mar-25-24 08:00AM	Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data (Business Wire)
Mar-11-24 06:53PM	The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024 (InvestorPlace) -12.11%
Mar-08-24 11:29PM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares (GuruFocus.com)
07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy (Business Wire)
Mar-04-24 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences (Business Wire)
Feb-07-24 10:42AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript (Insider Monkey)
10:02AM	Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-06-24 04:32PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:32PM	Arrowhead Pharmaceuticals Inc Reports Fiscal Q1 2024 Results with Strategic Focus on ... (GuruFocus.com)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results (Business Wire)
Jan-22-24 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results (Business Wire)
Jan-18-24 05:37AM	Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential (TipRanks)
Jan-09-24 03:02AM	Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 16,104 Shares (GuruFocus.com)
Jan-06-24 01:01PM	Arrowhead Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-05-24 05:00PM	Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million (Business Wire) +10.90%
11:02AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 9,952 Shares (GuruFocus.com)
Jan-03-24 07:00AM	Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock (Business Wire)
Dec-29-23 04:01PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Dec-24-23 09:01AM	Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares (GuruFocus.com)
Dec-21-23 07:30AM	Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease (Business Wire)
Dec-20-23 07:30AM	Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.23%
Dec-01-23 09:32AM	Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.29%
Nov-30-23 12:22PM	Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -26.85%

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hamilton James C	Chief Discovery/Trans Medicine	Jan 06 '25	Sale	19.82	32,729	648,824	272,122	Jan 07 09:28 PM
O'Brien Patrick	COO and General Counsel	Jan 06 '25	Sale	19.82	29,184	578,539	535,201	Jan 07 09:28 PM
O'Brien Patrick	COO and General Counsel	Jan 07 '25	Sale	19.69	8,000	157,520	527,201	Jan 07 09:28 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 06 '25	Sale	19.83	27,167	538,595	473,433	Jan 07 09:27 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Jan 07 '25	Sale	19.69	18,000	354,500	455,433	Jan 07 09:27 PM
Myszkowski Kenneth Allen	Officer	Jan 07 '25	Proposed Sale	19.69	10,000	196,877		Jan 07 05:01 PM
Myszkowski Kenneth Allen	Officer	Jan 07 '25	Proposed Sale	19.69	8,000	157,529		Jan 07 04:49 PM
O'Brien Patrick	Officer	Jan 07 '25	Proposed Sale	19.69	8,000	157,507		Jan 07 04:31 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '25	Sale	19.05	11,520	219,456	3,764,252	Jan 06 06:07 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	5,817	115,318		Jan 06 05:48 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	9,255	183,476		Jan 06 05:40 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.80	6,287	124,452		Jan 06 05:33 PM
Myszkowski Kenneth Allen	Officer	Jan 06 '25	Proposed Sale	19.82	5,817	115,320		Jan 06 05:26 PM
Hamilton James C	Officer	Jan 06 '25	Proposed Sale	19.82	32,729	648,743		Jan 06 05:19 PM
O'Brien Patrick	Officer	Jan 06 '25	Proposed Sale	19.82	29,184	578,456		Jan 06 05:05 PM
Anzalone Christopher Richard	Officer	Jan 02 '25	Proposed Sale	19.04	11,520	219,392		Jan 02 04:16 PM
OLUKOTUN ADEOYE Y	Director	Dec 27 '24	Sale	20.00	2,850	57,000	36,740	Dec 30 05:12 PM
OLUKOTUN ADEOYE Y	Director	Dec 27 '24	Proposed Sale	19.99	2,850	56,968		Dec 27 04:23 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 23 '24	Sale	19.59	12,563	246,109	3,775,772	Dec 23 04:39 PM
Anzalone Christopher Richard	Officer	Dec 23 '24	Proposed Sale	19.59	12,563	246,085		Dec 23 04:16 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 18 '24	Sale	21.24	26,712	567,486	3,688,335	Dec 20 06:04 PM
Waddill William D.	Director	Dec 17 '24	Sale	22.04	3,747	82,584	40,378	Dec 18 06:19 PM
Waddill William D.	Director	Dec 16 '24	Sale	21.90	3,748	82,081	44,125	Dec 18 06:19 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Sale	21.90	5,000	109,500	124,714	Dec 18 06:18 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Sale	22.04	547	12,056	124,167	Dec 18 06:18 PM
Vakiener Victoria	Director	Dec 16 '24	Sale	21.91	8,994	197,059	21,211	Dec 18 06:15 PM
Anzalone Christopher Richard	Officer	Dec 18 '24	Proposed Sale	21.24	26,712	567,415		Dec 18 04:41 PM
GIVEN DOUGLAS B	Director	Dec 17 '24	Proposed Sale	21.98	547	12,026		Dec 17 05:06 PM
Waddill William D.	Director	Dec 17 '24	Proposed Sale	22.03	3,747	82,552		Dec 17 04:53 PM
Waddill William D.	Director	Dec 16 '24	Proposed Sale	21.89	3,748	82,056		Dec 16 04:44 PM
Vakiener Victoria	Director	Dec 16 '24	Proposed Sale	21.91	8,994	197,066		Dec 16 04:30 PM
GIVEN DOUGLAS B	Director	Dec 16 '24	Proposed Sale	21.89	5,000	109,470		Dec 16 04:15 PM
Oliver Tracie	Chief Commercial Officer	Jul 02 '24	Sale	25.28	9,394	237,480	127,107	Jul 03 05:27 PM
Vakiener Victoria	Director	May 02 '24	Sale	23.31	1,799	41,935	30,205	May 06 06:04 PM
Hamilton James C	Chief Discovery/Trans Medicine	Apr 01 '24	Sale	28.03	6,000	168,180	204,851	Apr 03 06:05 PM
Lu Hongbo	Director	Mar 19 '24	Buy	28.00	1,000	28,000	32,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 20 '24	Buy	27.50	1,000	27,500	33,680	Mar 20 07:06 PM
Lu Hongbo	Director	Mar 18 '24	Buy	27.49	1,000	27,490	31,680	Mar 20 07:06 PM
Myszkowski Kenneth Allen	Chief Financial Officer	Mar 06 '24	Sale	35.19	40,000	1,407,600	400,600	Mar 08 05:54 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Option Exercise	14.54	57,499	836,035	3,772,547	Feb 02 05:25 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 31 '24	Sale	32.35	57,499	1,860,019	3,715,048	Feb 02 05:25 PM

Dollar change +0.28
Percentage change 0.77	%

PTGX Protagonist Therapeutics Inc daily Stock Chart

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR VTI CALF IWM XBI VXF AVUV IJT SPSM IWO

Index	RUT	P/E	13.81	EPS (ttm)	2.67	Insider Own	5.89%	Shs Outstand	59.52M	Perf Week	0.57%
Market Cap	2.19B	Forward P/E	-	EPS next Y	-1.30	Insider Trans	-7.54%	Shs Float	56.09M	Perf Month	-11.19%
Income	170.85M	PEG	-	EPS next Q	0.12	Inst Own	100.95%	Short Float	6.77%	Perf Quarter	-21.64%
Sales	323.80M	P/S	6.78	EPS this Y	270.31%	Inst Trans	6.73%	Short Ratio	5.66	Perf Half Y	3.11%
Book/sh	8.94	P/B	4.12	EPS next Y	-154.72%	ROA	36.59%	Short Interest	3.80M	Perf Year	49.13%
Cash/sh	7.86	P/C	4.68	EPS next 5Y	-	ROE	40.97%	52W Range	23.17 - 48.89	Perf YTD	-4.61%
Dividend Est.	-	P/FCF	9.57	EPS past 5Y	4.38%	ROI	31.48%	52W High	-24.69%	Beta	2.23
Dividend TTM	-	Quick Ratio	10.70	Sales past 5Y	3102.88%	Gross Margin	99.01%	52W Low	58.91%	ATR (14)	1.82
Dividend Ex-Date	-	Current Ratio	10.70	EPS Y/Y TTM	207.96%	Oper. Margin	46.05%	RSI (14)	39.62	Volatility	4.87% 4.24%
Employees	112	Debt/Eq	0.02	Sales Y/Y TTM	36565.08%	Profit Margin	52.76%	Recom	1.18	Target Price	57.64
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	6.70%	Payout	-	Rel Volume	0.72	Prev Close	36.54
Sales Surprise	50.20%	EPS Surprise	6.49%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	670.57K	Price	36.82
SMA20	-4.36%	SMA50	-10.38%	SMA200	-2.84%	Trades		Volume	485,306	Change	0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23

Show Previous Ratings

Jan-06-25 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Dec-19-24 04:05PM	Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 (ACCESSWIRE)
Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
04:05PM	Loading…
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
03:03PM	Loading…
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
08:20AM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-01-24 08:00AM	RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
07:00AM	Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
Jul-31-24 09:15AM	Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor (ACCESSWIRE)
Jul-22-24 07:00AM	Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 (ACCESSWIRE)
Jul-18-24 08:50AM	Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-11-24 06:00AM	3 Growth Stocks No One Is Watching (But They Should Be) (InvestorPlace)
Jun-28-24 04:07PM	Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 (Investor's Business Daily) +8.69%
12:11PM	Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024 (Associated Press)
05:44PM	Loading…
Jun-27-24 05:44PM	Protagonist Therapeutics Set to Join S&P SmallCap 600 (PR Newswire)
01:43PM	Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy? (Insider Monkey)
Jun-26-24 10:12PM	10 Best Healthcare Stocks to Buy Under $50 (Insider Monkey)
Jun-14-24 03:00AM	Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control (ACCESSWIRE)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace) +16.10%
May-31-24 07:30AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 (ACCESSWIRE)
May-14-24 04:05PM	Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress (ACCESSWIRE) +6.28%
May-07-24 11:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.12%
09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)
04:23PM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event (ACCESSWIRE)
04:05PM	Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +8.05%
04:05PM	Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
09:05AM	Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting (ACCESSWIRE)
Nov-01-23 04:05PM	Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis (ACCESSWIRE)
07:30AM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Oct-30-23 04:05PM	Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors (ACCESSWIRE)
Oct-09-23 07:00AM	Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications (ACCESSWIRE)
Oct-03-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Sep-05-23 07:30AM	Protagonist Therapeutics to Present at Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Aug-09-23 07:00AM	Protagonist Receives $34 Million from Warrant Exercises (ACCESSWIRE)
Aug-03-23 04:48PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-18-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Jul-05-23 09:33AM	Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment (Benzinga)
Jul-04-23 03:30AM	Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis (ACCESSWIRE)
Jun-30-23 08:50AM	Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-15-23 09:55AM	Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know (Zacks)
Jun-13-23 08:50AM	Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going (Zacks)
Jun-09-23 08:05AM	Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV (ACCESSWIRE)
Jun-06-23 07:30AM	Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress (ACCESSWIRE)
Jun-01-23 04:01PM	Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (ACCESSWIRE) +5.45%
May-26-23 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01% (Zacks)
May-12-23 03:14PM	Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment (Benzinga)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Option Exercise	8.04	26,000	209,040	62,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Option Exercise	8.04	5,529	44,453	51,973	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Sale	44.70	26,000	1,162,280	46,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Sale	45.60	5,529	252,122	46,444	Nov 27 07:11 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Option Exercise	7.75	175,000	1,356,000	359,611	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Option Exercise	12.17	30,450	370,576	286,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Sale	46.04	103,437	4,762,239	256,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Sale	45.50	19,191	873,190	266,983	Nov 27 07:09 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Option Exercise	21.58	1,727	37,269	429,935	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Sale	46.96	78,520	3,687,299	435,208	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 26 '24	Sale	46.25	21,480	993,450	408,455	Nov 27 07:08 PM
MOLINA ARTURO MD	Officer	Nov 27 '24	Proposed Sale	44.00	16,000	704,000		Nov 27 04:39 PM
MOLINA ARTURO MD	Officer	Nov 26 '24	Proposed Sale	45.00	16,000	720,000		Nov 26 07:39 PM
Gupta Suneel	Officer	Nov 26 '24	Proposed Sale	45.50	19,191	873,184		Nov 26 07:37 PM
Gupta Suneel	Officer	Nov 25 '24	Proposed Sale	46.46	103,437	4,805,683		Nov 25 05:40 PM
Dinesh Patel	CEO	Nov 25 '24	Proposed Sale	45.93	100,000	4,593,000		Nov 25 04:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '24	Sale	40.98	1,906	78,108	46,444	Nov 19 06:49 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Option Exercise	15.68	12,000	188,160	46,960	Sep 13 04:35 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Sale	44.49	14,203	631,872	34,960	Sep 13 04:35 PM
Waddill William D.	Director	Sep 10 '24	Option Exercise	12.88	8,000	103,040	20,000	Sep 12 07:38 PM
Waddill William D.	Director	Sep 10 '24	Sale	45.00	8,000	360,000	12,000	Sep 12 07:38 PM
Ali Asif	Officer	Sep 11 '24	Proposed Sale	44.49	14,203	631,855		Sep 11 06:15 PM
WILLIAM D WADDILL	Director	Sep 10 '24	Proposed Sale	45.00	8,000	360,000		Sep 10 04:17 PM
Waddill William D.	Director	Jul 24 '24	Option Exercise	12.88	8,000	103,040	20,000	Jul 26 04:31 PM
Waddill William D.	Director	Jul 24 '24	Sale	40.00	8,000	320,000	12,000	Jul 26 04:31 PM
Waddill William D.	Director	Jun 07 '24	Option Exercise	12.88	8,000	103,040	20,000	Jun 11 04:30 PM
Waddill William D.	Director	Jun 07 '24	Sale	35.00	8,000	280,000	12,000	Jun 11 04:30 PM
PATEL DINESH V PH D	President and CEO	Jun 07 '24	Sale	35.19	35,000	1,231,650	515,415	Jun 11 04:30 PM
Ali Asif	Chief Financial Officer	Apr 18 '24	Sale	25.11	1,234	30,986	37,163	Apr 19 08:05 PM
PATEL DINESH V PH D	President and CEO	Apr 01 '24	Sale	28.31	25,000	707,750	549,590	Apr 02 08:29 PM
SELICK HAROLD E	Director	Mar 07 '24	Option Exercise	1.89	6,490	12,266	27,996	Mar 11 08:00 PM
PATEL DINESH V PH D	President and CEO	Mar 01 '24	Sale	31.62	30,000	948,600	574,590	Mar 01 08:46 PM
Waddill William D.	Director	Mar 01 '24	Option Exercise	6.09	12,975	79,018	24,975	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Sale	31.34	12,975	406,636	12,000	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Option Exercise	12.17	12,000	146,040	52,645	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Sale	32.24	14,248	459,318	38,397	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Feb 29 '24	Sale	30.69	9,939	305,048	40,645	Mar 01 08:45 PM

ARWR

Arrowhead Pharmaceuticals Inc

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience